Hajj vaccinations—facts, challenges, and hope

International Journal of Infectious Diseases

Volumn 47, Issue , 2016, Pages 29-37

  Abd El Ghany, Moataz ^a,b   Sharaf, Hazem ^c   Hill Cawthorne, Grant A ^b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c Independent researcher   (Egypt)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hajj; Mass gathering; Preventive measures; Vaccination; Vaccines

Indexed keywords

CHOLERA VACCINE; HEPATITIS VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ARTICLE; DIARRHEA; DISEASE TRANSMISSION; ETHNICITY; GASTROENTERITIS; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INNATE IMMUNITY; INTESTINE INFECTION; MENINGOCOCCOSIS; MOLECULAR EPIDEMIOLOGY; MORBIDITY; PANDEMIC; PNEUMONIA; POLIOMYELITIS; RELIGION; SAUDI ARABIA; SEASONAL INFLUENZA; SEROPREVALENCE; VACCINATION; VIRUS HEPATITIS; VIRUS TRANSMISSION; CROWDING (AREA); HEALTH CARE POLICY; ISLAM; TRAVEL;

CROWDING; HEALTH POLICY; HUMANS; ISLAM; SAUDI ARABIA; TRAVEL; VACCINATION;

EID: 84979702172     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.05.024     Document Type: Article

References (164)

1. Ahmed, Q.A., Arabi, Y.M., Memish, Z.A., Health risks at the Hajj. Lancet 367 (2006), 1008–1015.
2. World Health Organization, World Bank. State of the world's vaccines and immunization. 3rd ed., 2009, WHO, Geneva.
3. Andre, F.E., Booy, R., Bock, H.L., Clemens, J., Datta, S.K., John, T.J., et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 86 (2008), 140–146.
4. Dagan, R., Klugman, K.P., Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 (2008), 785–795.
5. Cohen, R., Approaches to reduce antibiotic resistance in the community. Pediatr Infect Dis J 25 (2006), 977–980.
6. Kwong, J.C., Maaten, S., Upshur, R.E., Patrick, D.M., Marra, F., The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 49 (2009), 750–756.
7. Siegrist, C.A., Vaccine immunology. Vaccines, Sixth, 2013, Elsevier, 14–32.
8. Memish, Z.A., Al Rabeeah, A.A., Health conditions for travellers to Saudi Arabia for the Umra and pilgrimage to Mecca (Hajj)—2014. J Epidemiol Glob Health 4 (2014), 73–75.
9. WHO, Health conditions for travellers to Saudi Arabia for the pilgrimage to Mecca (Hajj), 2015. Wkly Epidemiol Rec 90:31 (2015), 381–392.
10. International Travel and Health, WHO, ITH, International travel and health. 2015, WHO, Geneva Available at: http://www.who.int/ith/en/ (accessed 10 May 2016).
11. Maiden, M.C., The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?. Philos Trans R Soc Lond B Biol Sci, 368, 2013, 20120147.
12. Funk, A., Uadiale, K., Kamau, C., Caugant, D.A., Ango, U., Greig, J., Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013–14. PLoS Curr, 6, 2014.
13. Delrieu, I., Yaro, S., Tamekloe, T.A., Njanpop-Lafourcade, B.M., Tall, H., Jaillard, P., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One, 6, 2011, e19513.
14. Xie, O., Pollard, A.J., Mueller, J.E., Norheim, G., Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 31 (2013), 2852–2861.
15. Swartley, J.S., Marfin, A.A., Edupuganti, S., Liu, L.J., Cieslak, P., Perkins, B., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 94 (1997), 271–276.
16. Beddek, A.J., Li, M.S., Kroll, J.S., Jordan, T.W., Martin, D.R., Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 77 (2009), 2989–2994.
17. Golubchik, T., Brueggemann, A.B., Street, T., Gertz, R.E. Jr., Spencer, C.C., Ho, T., et al. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event. Nat Genet 44 (2012), 352–355.
18. Xu, Y., Liu, B., Grondahl-Yli-Hannuksila, K., Tan, Y., Feng, L., Kallonen, T., et al. Whole-genome sequencing reveals the effect of vaccination on the evolution of Bordetella pertussis. Sci Rep, 5, 2015, 12888.
19. Day, T., Galvani, A., Struchiner, C., Gumel, A., The evolutionary consequences of vaccination. Vaccine 26:Suppl 3 (2008), C1–C3.
20. Wilder-Smith, A., Memish, Z., Meningococcal disease and travel. Int J Antimicrob Agents 21 (2003), 102–106.
21. Moore, P.S., Reeves, M.W., Schwartz, B., Gellin, B.G., Broome, C.V., Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 2 (1989), 260–263.
22. Wilder-Smith, A., Goh, K.T., Barkham, T., Paton, N.I., Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 36 (2003), 679–683.
23. Aguilera, J.F., Perrocheau, A., Meffre, C., Hahne, S., Group WW. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 8:8 (2002), 761–767.
24. Jones, D.M., Sutcliffe, E.M., Group A meningococcal disease in England associated with the Haj. J Infect 21 (1990), 21–25.
25. Klaber, R., Booy, R., El Bashir, H., Mifsud, A., Taylor, S., Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet, 360, 2002, 644.
26. Balmer, P., Borrow, R., Miller, E., Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51 (2002), 717–722.
27. Trotter, C.L., Andrews, N.J., Kaczmarski, E.B., Miller, E., Ramsay, M.E., Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004), 365–367.
28. Trotter, C.L., Maiden, M.C., Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 8 (2009), 851–861.
29. Read, R.C., Baxter, D., Chadwick, D.R., Faust, S.N., Finn, A., Gordon, S.B., et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384 (2014), 2123–2131.
30. Ridda, I., King, C., Rashid, H., Pneumococcal infections at Hajj: current knowledge gaps. Infect Disord Drug Targets 14 (2014), 177–184.
31. El-Sheikh, S.M., El-Assouli, S.M., Mohammed, K.A., Albar, M., Bacteria and viruses that cause respiratory tract infections during the pilgrimage (Haj) season in Makkah, Saudi Arabia. Trop Med Int Health 3 (1998), 205–209.
32. Baharoon, S., Al-Jahdali, H., Al Hashmi, J., Memish, Z.A., Ahmed, Q.A., Severe sepsis and septic shock at the Hajj: etiologies and outcomes. Travel Med Infect Dis 7 (2009), 247–252.
33. Asghar, A.H., Ashshi, A.M., Azhar, E.I., Bukhari, S.Z., Zafar, T.A., Momenah, A.M., Profile of bacterial pneumonia during Hajj. Indian J Med Res 133 (2011), 510–513.
34. Memish, Z.A., Almasri, M., Turkestani, A., Al-Shangiti, A.M., Yezli, S., Etiology of severe community-acquired pneumonia during the 2013 Hajj—part of the MERS-CoV surveillance program. Int J Infect Dis 25 (2014), 186–190.
35. O'Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:9693 (2009), 893–902.
36. McCullers, J.A., Rehg, J.E., Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186 (2002), 341–350.
37. van der Sluijs, K.F., van Elden, L.J., Nijhuis, M., Schuurman, R., Pater, J.M., Florquin, S., et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172 (2004), 7603–7609.
38. Kukavica-Ibrulj, I., Hamelin, M.E., Prince, G.A., Gagnon, C., Bergeron, Y., Bergeron, M.G., et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol 83 (2009), 1341–1349.
39. Shrestha, S., Foxman, B., Berus, J., van Panhuis, W.G., Steiner, C., Viboud, C., et al. The role of influenza in the epidemiology of pneumonia. Sci Rep, 5, 2015, 15314.
40. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83:373–84.
41. Centers for Disease Control and Prevention, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61 (2012), 816–819.
42. Tomczyk, S., Bennett, N.M., Stoecker, C., Gierke, R., Moore, M.R., Whitney, C.G., et al., Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 (2014), 822–825.
43. Leinonen, M., Sakkinen, A., Kalliokoski, R., Luotonen, J., Timonen, M., Makela, P.H., Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 5 (1986), 39–44.
44. Koskela, M., Leinonen, M., Haiva, V.M., Timonen, M., Makela, P.H., First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 5 (1986), 45–50.
45. Baltimore, R.S., New challenges in the development of a conjugate pneumococcal vaccine. JAMA 268 (1992), 3366–3367.
46. Shapiro, E.D., Berg, A.T., Austrian, R., Schroeder, D., Parcells, V., Margolis, A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 (1991), 1453–1460.
47. Andrews, N.J., Waight, P.A., George, R.C., Slack, M.P., Miller, E., Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 30 (2012), 6802–6808.
48. Jackson, L.A., Neuzil, K.M., Yu, O., Benson, P., Barlow, W.E., CAPITA Coauthors, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348:18 (2003), 1747–1755.
49. Honkanen, P.O., Keistinen, T., Miettinen, L., Herva, E., Sankilampi, U., Laara, E., et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17 (1999), 2493–2500.
50. Huss, A., Scott, P., Stuck, A.E., Trotter, C., Egger, M., Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180 (2009), 48–58.
51. Mangtani, P., Cutts, F., Hall, A.J., Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 3 (2003), 71–78.
52. Moberley, S., Holden, J., Tatham, D.P., Andrews, R.M., Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev, 1, 2013, CD000422.
53. Conaty, S., Watson, L., Dinnes, J., Waugh, N., The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 22 (2004), 3214–3224.
54. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000), 187–195.
55. Cutts, F.T., Zaman, S.M., Enwere, G., Jaffar, S., Levine, O.S., Okoko, J.B., et al., Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005), 1139–1146.
56. Shinefield, H.R., Black, S., Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 19 (2000), 394–397.
57. O'Brien, K.L., Moulton, L.H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362 (2003), 355–361.
58. Bonten, M.J., Huijts, S.M., Bolkenbaas, M., Coauthors C. Vaccine against pneumococcal pneumonia in adults. N Engl J Med, 373, 2015, 93.
59. Bonten, M.J., Huijts, S.M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 (2015), 1114–1125.
60. Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., Pierce, N., Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003), 1341–1348.
61. French, N., Gordon, S.B., Mwalukomo, T., White, S.A., Mwafulirwa, G., Longwe, H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362 (2010), 812–822.
62. Poehling, K.A., Talbot, T.R., Griffin, M.R., Craig, A.S., Whitney, C.G., Zell, E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295 (2006), 1668–1674.
63. Roca, A., Hill, P.C., Townend, J., Egere, U., Antonio, M., Bojang, A., et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med, 8, 2011, e1001107.
64. Andrade, A.L., Ternes, Y.M., Vieira, M.A., Moreira, W.G., Lamaro-Cardoso, J., Kipnis, A., et al. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One, 9, 2014, e98128.
65. Hammitt, L.L., Akech, D.O., Morpeth, S.C., Karani, A., Kihuha, N., Nyongesa, S., et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2 (2014), e397–e405.
66. Hammitt, L.L., Ojal, J., Bashraheil, M., Morpeth, S.C., Karani, A., Habib, A., et al. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. PLoS One, 9, 2014, e85459.
67. Brueggemann, A.B., Pai, R., Crook, D.W., Beall, B., Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog, 3, 2007, e168.
68. Beall, B., McEllistrem, M.C., Gertz, R.E. Jr., Wedel, S., Boxrud, D.J., Gonzalez, A.L., et al., Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44 (2006), 999–1017.
69. Metzger, D.W., Furuya, Y., Salmon, S.L., Roberts, S., Sun, K., Limited efficacy of antibacterial vaccination against secondary serotype 3 pneumococcal pneumonia following influenza infection. J Infect Dis 212 (2015), 445–452.
70. Mina, M.J., Klugman, K.P., McCullers, J.A., Live attenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice. J Infect Dis 208 (2013), 1281–1285.
71. Haworth, E., Barasheed, O., Memish, Z.A., Rashid, H., Booy, R., Prevention of influenza at Hajj: applications for mass gatherings. J R Soc Med 106 (2013), 215–223.
72. El Bashir, H., Haworth, E., Zambon, M., Shafi, S., Zuckerman, J., Booy, R., Influenza among U.K. pilgrims to Hajj, 2003. Emerg Infect Dis 10 (2004), 1882–1883.
73. Balkhy, H.H., Memish, Z.A., Bafaqeer, S., Almuneef, M.A., Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med 11 (2004), 82–86.
74. Rashid, H., Shafi, S., Booy, R., El Bashir, H., Ali, K., Zambon, M., et al. Influenza and respiratory syncytial virus infections in British Hajj pilgrims. Emerg Health Threats J, 1, 2008, e2.
75. Rashid, H., Shafi, S., Haworth, E., El Bashir, H., Memish, Z.A., Sudhanva, M., et al. Viral respiratory infections at the Hajj: comparison between UK and Saudi pilgrims. Clin Microbiol Infect 14 (2008), 569–574.
76. Alborzi, A., Aelami, M.H., Ziyaeyan, M., Jamalidoust, M., Moeini, M., Pourabbas, B., et al. Viral etiology of acute respiratory infections among Iranian Hajj pilgrims, 2006. J Travel Med 16 (2009), 239–242.
77. Memish, Z.A., Assiri, A.M., Hussain, R., Alomar, I., Stephens, G., Detection of respiratory viruses among pilgrims in Saudi Arabia during the time of a declared influenza A(H1N1) pandemic. J Travel Med 19 (2012), 15–21.
78. Memish, Z.A., Assiri, A.M., Alshehri, M., Hussain, R., Alomar, I., The prevalence of respiratory viruses among healthcare workers serving pilgrims in Makkah during the 2009 influenza A (H1N1) pandemic. Travel Med Infect Dis 10 (2012), 18–24.
79. Kandeel, A., Deming, M., Elkreem, E.A., El-Refay, S., Afifi, S., Abukela, M., et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis 17 (2011), 1266–1268.
80. Moattari, A., Emami, A., Moghadami, M., Honarvar, B., Influenza viral infections among the Iranian Hajj pilgrims returning to Shiraz, Fars Province, Iran. Influenza Other Respir Viruses 6 (2012), e77–e79.
81. Alfelali, M., Barasheed, O., Tashani, M., Azeem, M.I., El Bashir, H., Memish, Z.A., et al., Hajj Research Team. Changes in the prevalence of influenza-like illness and influenza vaccine uptake among Hajj pilgrims: a 10-year retrospective analysis of data. Vaccine 33 (2015), 2562–2569.
82. Lee, A.J., Das, S.R., Wang, W., Fitzgerald, T., Pickett, B.E., Aevermann, B.D., et al. Diversifying selection analysis predicts antigenic evolution of 2009 pandemic H1N1 influenza A virus in humans. J Virol 89 (2015), 5427–5440.
83. Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rimmelzwaan, G.F., Osterhaus, A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305 (2004), 371–376.
84. Bedford, T., Suchard, M.A., Lemey, P., Dudas, G., Gregory, V., Hay, A.J., et al. Integrating influenza antigenic dynamics with molecular evolution. Elife, 3, 2014, e01914.
85. Bhatt, S., Lam, T.T., Lycett, S.J., Leigh Brown, A.J., Bowden, T.A., Holmes, E.C., et al., Combating Swine Influenza C, Pybus OG. The evolutionary dynamics of influenza A virus adaptation to mammalian hosts. Philos Trans R Soc Lond B Biol Sci, 368, 2013, 20120382.
86. Drummond, A.J., Ho, S.Y., Phillips, M.J., Rambaut, A., Relaxed phylogenetics and dating with confidence. PLoS Biol, 4, 2006, e88.
87. Strelkowa, N., Lassig, M., Clonal interference in the evolution of influenza. Genetics 192 (2012), 671–682.
88. Tharakaraman, K., Sasisekharan, R., Influenza surveillance: 2014–2015 H1N1 “swine”-derived influenza viruses from India. Cell Host Microbe 17 (2015), 279–282.
89. Belanov, S.S., Bychkov, D., Benner, C., Ripatti, S., Ojala, T., Kankainen, M., et al. Genome-wide analysis of evolutionary markers of human influenza A(H1N1)pdm09 and A(H3N2) viruses may guide selection of vaccine strain candidates. Genome Biol Evol 7:12 (2015), 3472–3483.
90. Broberg, E., Snacken, R., Adlhoch, C., Beaute, J., Galinska, M., Pereyaslov, D., et al., Region WHOE, the European Influenza Surveillance N. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill, 20(4), 2015, 10.2807/1560-7917.ES2015.20.4.21023.
91. Flannery, B., Clippard, J., Zimmerman, R.K., Nowalk, M.P., Jackson, M.L., Jackson, L.A., et al., Centers for Disease Control and Prevention. Early estimates of seasonal influenza vaccine effectiveness—United States, January 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 10–15.
92. Rondy, M., Launay, O., Puig-Barbera, J., Gefenaite, G., Castilla, J., de Gaetano Donati, K., et al., European hospital IVEn, Moren A. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill, 20(2), 2015, 10.2807/1560-7917.ES2015.20.2.21011.
93. Valenciano, M., Kissling, E., Reuss, A., Jimenez-Jorge, S., Horvath, J.K., Donnell, J.M., et al. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogeneous results by country against A(H3N2). Vaccine 33 (2015), 2813–2822.
94. Alfelali, M., Khandaker, G., Booy, R., Rashid, H., Mismatching between circulating strains and vaccine strains of influenza: effect on Hajj pilgrims from both hemispheres. Hum Vaccin Immunother 12:3 (2016), 709–715.
95. Cao, W., Kim, J.H., Chirkova, T., Reber, A.J., Biber, R., Shay, D.K., et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev Vaccines 10 (2011), 1529–1537.
96. Engler, R.J., Nelson, M.R., Klote, M.M., VanRaden, M.J., Huang, C.Y., Cox, N.J., et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med 168 (2008), 2405–2414.
97. Frenck, R.W. Jr., Belshe, R., Brady, R.C., Winokur, P.L., Campbell, J.D., Treanor, J., et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 29 (2011), 5666–5674.
98. DiazGranados, C.A., Saway, W., Gouaux, J., Baron, M., Baker, J., Denis, M., et al. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. Vaccine 33:51 (2015), 7188–7193.
99. Couch, R.B., Winokur, P., Brady, R., Belshe, R., Chen, W.H., Cate, T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 (2007), 7656–7663.
100. DiazGranados, C.A., Dunning, A.J., Jordanov, E., Landolfi, V., Denis, M., Talbot, H.K., High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 31 (2013), 861–866.
101. Falsey, A.R., Treanor, J.J., Tornieporth, N., Capellan, J., Gorse, G.J., Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200 (2009), 172–180.
102. Tsang, P., Gorse, G.J., Strout, C.B., Sperling, M., Greenberg, D.P., Ozol-Godfrey, A., et al. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Vaccine 32 (2014), 2507–2517.
103. Xiang, K., Ying, G., Yan, Z., Shanshan, Y., Lei, Z., Hongjun, L., et al. Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother 11 (2015), 1209–1222.
104. Price, G.E., Lo, C.Y., Misplon, J.A., Epstein, S.L., Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol 88 (2014), 6019–6030.
105. Garcia, M., Misplon, J.A., Price, G.E., Lo, C.Y., Epstein, S.L., Age dependence of immunity induced by a candidate universal influenza vaccine in mice. PLoS One, 11, 2016, e0153195.
106. Everitt, A.R., Clare, S., Pertel, T., John, S.P., Wash, R.S., Smith, S.E., et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484 (2012), 519–523.
107. Johnson, D.F., Leder, K., Torresi, J., Hepatitis B and C infection in international travelers. J Travel Med 20 (2013), 194–202.
108. Memish, Z.A., Venkatesh, S., Ahmed, Q.A., Travel epidemiology: the Saudi perspective. Int J Antimicrob Agents 21 (2003), 96–101.
109. Gatrad, A.R., Sheikh, A., Hajj and risk of blood borne infections. Arch Dis Child, 84, 2001, 375.
110. Rafiq, S.M., Rashid, H., Haworth, E., Booy, R., Hazards of hepatitis at the Hajj. Travel Med Infect Dis 7 (2009), 239–246.
111. Ott, J.J., Stevens, G.A., Groeger, J., Wiersma, S.T., Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
112. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
113. El Beltagy, K.E., Al Balawi, I.A., Almuneef, M., Memish, Z.A., Prevalence of hepatitis B virus markers among blood donors in a tertiary hospital in Tabuk, northwestern Saudi Arabia. Int J Infect Dis 12 (2008), 495–499.
114. Mahaba, H., el-Tayeb Ael, K., Elbaz, H., The prevalence of antibodies to hepatitis C virus in Hail region, Saudi Arabia. J Egypt Public Health Assoc 74 (1999), 69–80.
115. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
116. World Health Organization, Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec 75 (2000), 38–42.
117. World Health Organization, WHO position paper on hepatitis A vaccines—June 2012. Wkly Epidemiol Rec 87 (2012), 261–276.
118. Shepard, C.W., Simard, E.P., Finelli, L., Fiore, A.E., Bell, B.P., Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28 (2006), 112–125.
119. World Health Organization, Hepatitis B vaccines: WHO position paper—recommendations. Vaccine 28 (2010), 589–590.
120. Vryheid, R.E., Kane, M.A., Muller, N., Schatz, G.C., Bezabeh, S., Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 19 (2000), 1026–1037.
121. Infectious diseases related to travel—hepatitis B. 2011. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm (accessed 10 May 2016).
122. World Health Organization, International travel and health. 2012, WHO, Geneva Available at: http://www.who.int/ith/en/ (accessed 10 May 2016).
123. Zuckerman, J.N., Van Damme, P., Van Herck, K., Loscher, T., Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Med Infect Dis 1 (2003), 219–226.
124. Ghadiri, K., Vaziri, S., Afsharian, M., Jahanbaksh, A., Mansouri, F., Sayad, M., et al. Comparison of the accelerated and standard vaccination schedules against hepatitis B in healthcare workers. J Res Med Sci 17 (2012), 934–937.
125. Van Herck, K., Leuridan, E., Van Damme, P., Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sex Transm Infect 83 (2007), 426–432.
126. Murdoch, D.L., Goa, K., Figgitt, D.P., Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs 63 (2003), 2625–2649.
127. Wolters, B., Muller, T., Ross, R.S., Clauberg, R., Werfel, U., Roggendorf, H., et al. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 5 (2009), 248–253.
128. Diop, O.M., Burns, C.C., Sutter, R.W., Wassilak, S.G., Kew, O.M., Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 640–646.
129. Burns, C.C., Diop, O.M., Sutter, R.W., Kew, O.M., Vaccine-derived polioviruses. J Infect Dis 210:Suppl 1 (2014), S283–S293.
130. Polio Eradication & Endgame Midterm Review. 2015. Available at: http://www.polioeradication.org (accessed 10 May 2016).
131. Hagan, J.E., Wassilak, S.G., Craig, A.S., Tangermann, R.H., Diop, O.M., Burns, C.C., et al., Centers for Disease Control and Prevention. Progress toward polio eradication—worldwide, 2014–2015. MMWR Morb Mortal Wkly Rep 64 (2015), 527–531.
132. Kew, O.M., Cochi, S.L., Jafari, H.S., Wassilak, S.G., Mast, E.E., Diop, O.M., et al., Centers for Disease Control and Prevention. Possible eradication of wild poliovirus type 3—worldwide, 2012. MMWR Morb Mortal Wkly Rep 63 (2014), 1031–1033.
133. World Health Organization, Global vaccine action plan 2011–2020. 2013, WHO, Geneva Available at: http://www.who.int (accessed 10 May 2016).
134. World Health Organization. Replacing trivalent OPV with bivalent OPV. Geneva WHO. 2015, Available at: http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/en/ (accessed 10 May 2016).
135. Initiative GPE. Response to type 2 vaccine-derived polioviruses prior to global tOPV withdrawal. Interim guidelines. 2015. Available at: http://www.polioeradication.org/Resourcelibrary/Resourcesforpolioeradicators.aspx (accessed 10 May 2016).
136. Clemens, J.D., Sack, D.A., Harris, J.R., Van Loon, F., Chakraborty, J., Ahmed, F., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335 (1990), 270–273.
137. Sanchez, J.L., Vasquez, B., Begue, R.E., Meza, R., Castellares, G., Cabezas, C., et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344 (1994), 1273–1276.
138. Khatib, A.M., Ali, M., von Seidlein, L., Kim, D.R., Hashim, R., Reyburn, R., et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 12 (2012), 837–844.
139. Lucas, M.E., Deen, J.L., von Seidlein, L., Wang, X.Y., Ampuero, J., Puri, M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352 (2005), 757–767.
140. Luquero, F.J., Grout, L., Ciglenecki, I., Sakoba, K., Traore, B., Heile, M., et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370 (2014), 2111–2120.
141. Clemens, J.D., Sack, D.A., Rao, M.R., Chakraborty, J., Khan, M.R., Kay, B., et al. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J Infect Dis 166 (1992), 1029–1034.
142. Black, R.E., Levine, M.M., Clements, M.L., Young, C.R., Svennerholm, A.M., Holmgren, J., Protective efficacy in humans of killed whole-Vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 55 (1987), 1116–1120.
143. Hill, D.R., Ford, L., Lalloo, D.G., Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 6 (2006), 361–373.
144. Lewnard, J.A., Antillon, M., Gonsalves, G., Miller, A.M., Ko, A.I., Pitzer, V.E., Strategies to prevent cholera introduction during international personnel deployments: a computational modeling analysis based on the 2010 Haiti outbreak. PLoS Med, 13, 2016, e1001947.
145. Enzler, M.J., Berbari, E., Osmon, D.R., Antimicrobial prophylaxis in adults. Mayo Clin Proc 86 (2011), 686–701.
146. World Health Organization, Antimicrobial resistance: global report on surveillance 2014. 2014, WHO, Geneva doi: 978 92 4 156474 8, http://www.who.int/drugresistance/documents/surveillancereport/en/.
147. Olaitan, A.O., Dia, N.M., Gautret, P., Benkouiten, S., Belhouchat, K., Drali, T., et al. Acquisition of extended-spectrum cephalosporin- and colistin-resistant Salmonella enterica subsp. enterica serotype Newport by pilgrims during Hajj. Int J Antimicrob Agents 45 (2015), 600–604.
148. Azeem, M., Tashani, M., Barasheed, O., Heron, L., Hill-Cawthorne, G.A., Haworth, E., et al. Knowledge, Attitude and Practice (KAP) survey concerning antimicrobial use among Australian Hajj pilgrims. Infect Disord Drug Targets 14:2 (2014), 125–132.
149. Hill, D.R., Ericsson, C.D., Pearson, R.D., Keystone, J.S., Freedman, D.O., Kozarsky, P.E., et al., Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 (2006), 1499–1539.
150. Alqahtani, A.S., Alfelali, M., Arbon, P., Booy, R., Rashid, H., Burden of vaccine preventable diseases at large events. Vaccine 33:48 (2015), 6552–6563.
151. Sridhar, S., Belhouchat, K., Drali, T., Benkouiten, S., Parola, P., Brouqui, P., et al. French Hajj pilgrims’ experience with pneumococcal infection and vaccination: a knowledge, attitudes and practice (KAP) evaluation. Travel Med Infect Dis 13 (2015), 251–255.
152. Alqahtani, A.S., Sheikh, M., Wiley, K., Heywood, A.E., Australian Hajj pilgrims’ infection control beliefs and practices: insight with implications for public health approaches. Travel Med Infect Dis 13 (2015), 329–334.
153. Aberle, J.H., Popow-Kraupp, T., Kreidl, P., Laferl, H., Heinz, F.X., Aberle, S.W., Influenza A and B viruses but not MERS-CoV in Hajj pilgrims, Austria, 2014. Emerg Infect Dis 21 (2015), 726–727.
154. Sette, A., Rappuoli, R., Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33 (2010), 530–541.
155. Bettinger, J.A., Scheifele, D.W., Halperin, S.A., Vaudry, W., Findlow, J., Borrow, R., et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 32 (2013), 124–130.
156. Vogel, U., Taha, M.K., Vazquez, J.A., Findlow, J., Claus, H., Stefanelli, P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13 (2013), 416–425.
157. Macken, C., Lu, H., Goodman, J., Broykin, L.M., The value of a database in surveillance and vaccine selection. International Congress Series 10 (2001), 103–106.
158. Squires, R.B., Noronha, J., Hunt, V., Garcia-Sastre, A., Macken, C., Baumgarth, N., et al. Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses 6 (2012), 404–416.
159. Sayers, S., Ulysse, G., Xiang, Z., He, Y., Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol, 2012, 2012, 831486.
160. Xiang, Z., Todd, T., Ku, K.P., Kovacic, B.L., Larson, C.B., Chen, F., et al. VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 36 (2008), D923–D928.
161. He, Y., Racz, R., Sayers, S., Lin, Y., Todd, T., Hur, J., et al. Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res 42 (2014), D1124–D1132.
162. Li, W., Implementation of a mobile-based surveillance system in Saudi Arabia for the 2009 Hajj. Online J Public Health Inform, 5(1), 2013, 137.
163. Memish, Z.A., Zumla, A., Alhakeem, R.F., Assiri, A., Turkestani, A., Al Harby, K.D., et al. Hajj: infectious disease surveillance and control. Lancet 383 (2014), 2073–2082.
164. Alqahtani, A.S., BinDhim, N.F., Tashani, M., Willaby, H.W., Wiley, K.E., Heywood, A.E., et al. Pilot use of a novel smartphone application to track traveller health behaviour and collect infectious disease data during a mass gathering: Hajj pilgrimage 2014. J Epidemiol Glob Health 2015, 2015, 10.1016/j.jegh.2015.07.005.